Literature DB >> 1904269

Experience with salvage regimens at M.D. Anderson Hospital.

F Cabanillas1.   

Abstract

With the intent of using active regimens in the front-line setting, new combinations of chemotherapy have been tested as salvage treatment in lymphoma patients at M.D. Anderson Hospital. Combinations based on ifosfamide plus etoposide, including IMVP-16 (ifosfamide/methotrexate/etoposide) and MIME (methyl-GAG/ifosfamide/methotrexate/etoposide) resulted in overall and complete responses (CRs) of 60 and 25%, respectively. Long-term follow-up of MIME indicates a 25% cure rate in intermediate-grade lymphoma patients who achieve CR. The in vitro synergism of platinum and high-dose cytarabine recently has been confirmed clinically. A study is currently under way to evaluate the effect of integrating MINE (mesna/ifosfamide/mitoxantrone/etoposide) and ESHAP (etoposide/methyl prednisolone/cytarabine/platinum) into one protocol.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1904269     DOI: 10.1093/annonc/2.suppl_1.31

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  3 in total

1.  Salvage therapy for non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide, and cisplatin.

Authors:  N Haim; E Rosenblatt; M Wollner; M Ben-Shahar; R Epelbaum; E Robinson
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide.

Authors:  N Haim; M Ben-Shahar; R Epelbaum
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

3.  ESHAP salvage therapy for refractory and relapsed non-Hodgkin's lymphoma: a single center experience.

Authors:  Sang Hyoung Park; Shin Kim; Ok Bae Ko; Ja Eun Koo; Danbi Lee; Yong Pil Jeong; Jooryung Huh; Sung-Bae Kim; Sang We Kim; Jae-Lyun Lee; Cheolwon Suh
Journal:  Korean J Intern Med       Date:  2006-09       Impact factor: 2.884

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.